China

Lonza Licenses NeuroPortal Blood-Brain Barrier Technology to China Medical System

Lonza grants CMS global rights to newly acquired TfR1 technology in up to two neurodegenerative disease targets.  Lonza’s NeuroPortal...

 November 17, 2026 | News

Delonix Bioworks and A*STAR IDL Collaborate on Vaccines Against Drug-Resistant Klebsiella pneumoniae

Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has ente...

 November 18, 2026 | News

China’s NMPA Accepts Akeso’s Ivonescimab Application for First-Line Biliary Tract Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental ...

 November 18, 2026 | News

The 10 New Drugs Japan Expects to Sell Most: Peak-Sales Forecasts From Every 2026 NHI Listing Round

On 13 November, 16 new medicines joined Japan's National Health Insurance (NHI) price list. It was the last of the seven listing rounds Japan now runs each...

 November 17, 2026 | Analysis

Orphalan Expands Phase 3 Wilson Disease Trial to China

Phase 3 trial evaluates the safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine ...

 November 17, 2026 | News

Zai Lab Secures China NRDL Coverage for Five Medicines, Including Two New Listings

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, announced that five of its commercial medicines in China have b...

 November 16, 2026 | News

IASO Bio Secures China IND Approval for In Vivo CAR-T Therapy IASO208

First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated directl...

 November 12, 2026 | News

Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery

Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...

 November 11, 2026 | News

Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...

 November 11, 2026 | News

ZEISS Showcases China-Approved PT LUNANA Lens for Myopia at CIIE

ZEISS Medical Technology showcased at CIIE its next-generation aspheric phakic intraocular lens (pIOL) PT LUNANA® to address myopia in China, a growing...

 November 11, 2026 | News

Ribo Files EU Phase I Trial Application for Dual-Target siRNA Therapy SR122

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase...

 November 11, 2026 | News

Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial

SINTBILO®  (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...

 November 10, 2026 | News

China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

 November 09, 2026 | News

Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer

Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...

 November 06, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close